Abstract 252P
Background
RCC accounts for nearly 4% of all malignancies, in the Philippines, RCC ranks as the 15th most common cancer in 2018. The National Kidney and Transplant institute Cancer registry ranks RCC as the institute’s 4th most common malignancy at 10%. Studies to improve the diagnostic work up and follow up of this rare malignancy but apparently common in this institution can contribute for a better management and characterization of RCC.
Methods
This is a retrospective cohort study which included all patients who underwent nephrectomy for localized renal cell cancer from January 2017 to December 2021.
Results
There were 464 eligible patients included in this study. Clinical factors associated with recurrence of RCC upon multivariate analysis are bilateral sidedness, pT2 and beyond, WHO Grade 3-4, tumor encompassing the entire kidney, sarcomatoid and rhabdoid features, tumor necrosis, tumor thrombus, lymphovascular space invasion and positive surgical margins. Most common sites of recurrence was lungs (58.33%) followed by lymph nodes (45.83%) then bones (20.83%).
Conclusions
Presence of poor prognostic factors as well as positive lymph nodes are highly associated with local and distant RCC recurrence. A more stringent follow up with appropriate imaging may allow early intervention of metastatic diseases and possible consideration of lymph node dissection may improve recurrence free survival.
Clinical trial identification
Editorial acknowledgement
101 Health research.
Legal entity responsible for the study
The author.
Funding
National Kidney and Transplant Institute.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract